Revvity Signals || Signals One™

EDITORIAL SECTION

  • STRATEGY

    Smarter Pharma

    Quality management systems QMS are the backbone of pharmaceutical manufacturing ensuring safe products

  • EXPERT Talk

    Compliance to Competitive Advantage in Pharma Supply

    Compliance gets you through an audit Resilience gets medicines to patients on the day something unexpected happens The DSCSAs enhanced requirements took effect November but real interoperability required three more rounds of accommodation phased implementation with the smalldispenser

KNOWLEDGE BANK

TOP ARTICLES

  • 5

    Fundamentals of Pharmaceutical Formulation Development

    Kate Williamson

    Drug innovation is a principal responsibility of pharmaceutical formulation development that provides the drug with stability, bioavailability, and adherence in the patients. Researchers can make mole...

press releases Read more...

Genmab and Incyte Announce Clinical Trial Collaboration in Metastatic Colorectal Cancer

Genmab AS and Incyte announced a clinical trial collaboration to evaluate petosemtamab Genmabs investigational IgGbispecific antibody targeting the epidermal growth factor receptor EGFR and leucinerich repeat containing Gproteincoupled receptor LGR in combination with INCB Incytes investigational p...

CasZyme and Cirena to Collaborate on Developing Longer Guide RNAs to Optimise Cas12l Performance

CasZyme and Cirena have today signed an agreement that will see the two companies collaborate on further optimising the editing efficiency of CasZymes Casl CRISPR nuclease in humanrelevant applications using Cirenas synthetic nt guide RNAs

Fortrea and Omico Collaboration to Advance Biomarker-led Oncology Drug Development

Fortrea a leading global contract research organization CRO and Omico Australias leading precision oncology screening and trial matching organization today announced a collaboration to accelerate precision oncology research by helping connect cancer patients to biomarkermatched clinical trials By co...

ZEGFROVY® (sunvozertinib) now available in the US for patients with previously treated non-small cell lung cancer with EGFR exon 20 insertion mutations

AstraZeneca today announced the US availability of ZEGFROVY sunvozertinib for the treatment of adults with locally advanced or metastatic nonsmall cell lung cancer NSCLC whose tumors have epidermal growth factor receptor EGFR exon insertion mutations as detected by an FDAapproved test

26 - 28

Oct 2026

ACHEMA Middle East 2026

RICEC, Riyadh, KSA, Saudi Arab...

26 - 28

Oct 2026

World Orphan Drug Congress

RAI, Amsterdam, Netherlands

27 - 28

Oct 2026

Pharma Manufacturing & Automation Convention 2026

Novotel Hyderabad Airport, Ind...

28 - 30

Oct 2026

02 - 04

Nov 2026

Pharma Forum EMEA 2026

Dom Pedro Lisboa Hotel, Lisbon...

02 - 04

Nov 2026

Cancer R&D 2026

Houston, TX, USA

03 - 05

Nov 2026

10th Dermatology Drug Development

Boston, Massachusetts at The C...

03 - 04

Nov 2026

PDA Aseptic Processing of Biopharma Conference

Sheraton Grand Incheon Hotel,...

LATEST NEWS Read more...

Sacituzumab Tirumotecan (Sac-TMT) Reduced the Risk of Death by 32% and the Risk of Disease Progression or Death by 41% Compared to Chemotherapy in Patients With Recurrent Endometrial Cancer

Merck known as MSD outside of the United States and Canada today announced the first presentation of results from the pivotal Phase TroFuse trial evaluating sacituzumab tirumotecan sacTMT an investigational TROPdirected antibodydrug conjugate ADC being developed in collaboration with KelunBiotech i...

Tempus Receives IVDR Certification for xR RNA Sequencing for Solid Tumor Profiling

Tempus AI Inc announced that its xR assay has received certification under the European Unions In Vitro Diagnostic Regulation IVDR as a Class C in vitro diagnostic device The certification covers Tempus quality management system for nextgeneration sequencing devices for cancer genomic profiling to s...

Georgiamune and Menarini Group Enter Exclusive Global License and Collaboration Agreement for GIM-621, a First-in-Class Oral Immuno-Oncology Agent

The Menarini Group a leading international pharmaceutical and diagnostics company and Stemline Therapeutics Inc Stemline a whollyowned subsidiary of the Menarini Group focused on bringing transformational oncology treatments to cancer patients along with Georgiamune Inc a clinicalstage biotechnology...

LGM Pharma Acquires Sannova Analytical, Expanding cGMP Analytical and GLP Bioanalytical Services

LGM Pharma a leading provider of tailored API sourcing contract analytical testing and drug development services today announced it has acquired Sannova Analytical a contract research laboratory headquartered in Somerset NJ The acquisition expands LGM Pharmas analytical testing services business by...

AI Proteins Announces Research Collaboration and License Agreement With Astellas Pharma to Discover and Develop Novel Miniprotein-Based Therapeutics Valued at Over $400 Million

AI Proteins Inc a biotechnology company that utilizes computational de novo protein design to create therapeutic miniproteins today announced it has entered into a Research Collaboration and License Agreement with Astellas Innovation Management LLC an affiliate of Astellas Pharma Inc TSE to discove...

Okomera Announces Trade Agreement with Servier to Use Tumor Miniaturization Technology in Cancer Research

Okomera a TechBio company that personalizes cancer management with its technology combining minivatars tumor microfluidics and AI imaging today announced the signing of a commercial agreement with Servier an independent international pharmaceutical group